347544 RESULTS
COMMENT I want to say "thanks" to scientists for developing tools that can identify people at greatest risk for the disease, and expedite their recruitment. This is great work. maryjsmith350_213486 0
COMMENT Following up on Jeanne's request for reminiscences, I recall that Allen's discussion with song and dance was entertaining and informative. Steve Younkin was there, too. I remember Dale showing a civil war picture and pointing to a gun and statin
COMMENT This study provides interesting new insights into the possible disease relevance of the accumulation of endolysosomal organelles within the dystropic axons that surround amyloid plaques. In a parallel effort, my group has recently identified a distinct JI
COMMENT The Lancet Commission report is an heroic achievement but it was rather selective in the risk factors that it reported and which formed the basis of the widely-cited claim that more than a third of dementia cases might be prevented if all the modifiable r
COMMENT Aducanumab may work because it reduces both insouble and soluble Abeta. However it may be incorrect to believe that the beneficial effect can only be manifest in early or prodromal disease because there is too much damage in more advanced cases. Instead i
COMMENT These findings were was novel to me, and show how the immune system is always surprising us. Systemic inflammation needs to be taken into account when considering cell-based therapy. There are multiple clinical trials planned for treatment of Parkinson’s
COMMENT I met Rahul at a conference for early investigators several years back, and we all found it easy to become his colleague and friend. I was struck by his seemingly boundless energy, intelligence, and creativity. It's difficult for me to process the lo
COMMENT We are watching the approval of aducanumab with interest, given that we had cloned the antibody to evaluate whether a combination with therapeutic ultrasound would be more effective in clearing amyloid and improving cognitive functions in the APP23 mouse
COMMENT We appreciate the insightful comment by Drs. Ezzat and Espay and are grateful that our colleagues noticed an incorrect statement with respect to the MS-based levels of Aβwt1-42, which were indeed lower in mutation carriers as compared to control subjects.
